Research programme: antibacterial therapeutics - Selmod
Latest Information Update: 05 Feb 2021
Price :
$50 *
At a glance
- Originator TU Berlin
- Developer Selmod
- Class Antibacterials
- Mechanism of Action Bacterial DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gram-negative infections
Most Recent Events
- 13 Jan 2021 Research programme: antibacterial therapeutics - Selmod is available for licensing as of 13 Jan 2021. https://www.selmod.com/company.html
- 13 Jan 2021 Selmod in-licenses gyrase inhibitors from TU Berlin (Selmod website, January 2021)
- 13 Jan 2021 Preclinical trials in Gram-negative infections in Switzerland (unspecified route)